Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Histotripsy in Advanced Intrahepatic Cholangiocarcinoma
NCT07766187Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Aug 2032
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in intrahepatic cholangiocarcinoma (ICC), sponsored by University of Wisconsin–Madison. Primary endpoints: Number of Participants with Increase in Adaptive Immune System Response following histotripsy and Percent of Participants Experiencing Immune-mediated Adverse Events within 30 days of histotripsy. Started Nov 2026; status: recruiting.
02
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07766187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766187.